Clinical trial
Malignant Pleural Effusion With ZD6474
NCT00402896 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00402896 |
|---|---|
| Title | Malignant Pleural Effusion With ZD6474 |
| Official title | Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | United States Department of Defense U.S. Fed AstraZeneca Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Pleural Effusion |
| Intervention type | Drug |
| Interventions | ZD6474 |
| Enrollment | 28 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2014 |
| Completion | Jun 1, 2014 |
| First posted | Nov 22, 2006 |
| Last update posted | Mar 9, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: